Evidence map›Paper›PMID 40535732›Full record

ArticleTherapeutic advances in medical oncology2025

Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring

Masashi Ishihara, Takahisa Kawamura, Yukiko Namba, Yuki Takeyasu, Yukihiro Hasegawa, Yuki Sato, Yoshiki Negi, Tomohiro Oba, Toshiyuki Sumi, Hirokuni Hirata and 40 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

50 authors.

Masashi IshiharaDivision of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0001-5333-4969
Takahisa KawamuraDepartment of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Yukiko NambaDepartment of Respiratory Medicine, Juntendo University Urayasu Hospital, Chiba, Japan.
Yuki TakeyasuDepartment of Thoracic Oncology, Kansai Medical University, Osaka, Japan.
Yukihiro HasegawaDepartment of Respiratory Medicine, Aomori Prefectural Central Hospital, Aomori, Japan.
Yuki SatoDepartment of Respiratory Medicine, Kobe City Medical Center General Hospital, Hyogo, Japan.
Yoshiki NegiDepartment of Respiratory Medicine and Hematology, School of Medicine, Hyogo Medical University, Hyogo, Japan.ORCID https://orcid.org/0009-0006-5059-4654
Tomohiro ObaDepartment of Respiratory Medicine, Saitama Red Cross Hospital, Saitama, Japan.
Toshiyuki SumiDepartment of Respiratory Medicine, Hakodate Goryoukaku Hospital, Hokkaido, Japan.
Hirokuni HirataDepartment of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center, Saitama, Japan.
Hidemitsu FunabashiDivision of Respiratory Medicine, Department of Internal Medicine, Matsudo City General Hospital, Chiba, Japan.
Yuko OyaDepartment of Respiratory Medicine & Clinical Allergy, Fujita Health University, Aichi, Japan.
Hajime KikuchiDepartment of Respiratory Medicine, Obihiro-Kousei General Hospital, Hokkaido, Japan.
Naoko KatsuradaDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Hyogo, Japan.
Takeshi NakataniDepartment of Respiratory Medicine, Osaka Police Hospital, Osaka, Japan.
Keiko TanimuraDepartment of Respiratory Medicine, Fukuchiyama City Hospital, Kyoto, Japan.
Taku NakagawaDepartment of Thoracic Surgery, Omagari Kosei Medical Center, Akita, Japan.
Naoya TakedaDepartment of Respiratory Medicine, Kariya Toyota General Hospital, Aichi, Japan.
Takahiro AsamiDepartment of Internal Medicine, Sano Kosei General Hospital, Tochigi, Japan.
Osamu HonjoDepartment of Respiratory Medicine, Sapporo Minami-Sanjo Hospital, Hokkaido, Japan.
Hiromi NagashimaDivision of Pulmonary Medicine, Department of Internal Medicine, Iwate Medical University School of Medicine, Iwate, Japan.
Takumi YamauraDepartment of Thoracic Surgery, Takeda General Hospital, Fukushima, Japan.
Norihiko HataDepartment of Respiratory Medicine, Kawaguchi Municipal Medical Center, Saitama, Japan.
Miyako KitazonoDepartment of Respiratory Medicine and Oncology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.
Naoya NishiokaDepartment of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Akihiro TamiyaNational Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.
Yuichi SakamoriDepartment of Respiratory Medicine, Japanese Red Cross Society, Wakayama Medical Center, Wakayama, Japan.
Ryota ShigakiDivision of Respiratory Medicine and Neurology, Department of Internal Medicine, Asahikawa Medical University, Hokkaido, Japan.
Kyoichi KairaDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
Ryoichi HondaDepartment of Respiratory Medicine, Asahi General Hospital, Chiba, Japan.
Takashi MatsuiDepartment of Respiratory Medicine, Respiratory Disease Center, Seirei Mikatahara General Hospital, Shizuoka, Japan.
Eriko SuzukiDivision of Thoracic Surgery, Respiratory Disease Center, Seirei Mikatahara General Hospital, Shizuoka, Japan.
Kentaro ItoRespiratory Center, Matsusaka Municipal Hospital, Mie, Japan.
Kojiro OtsukaDepartment of Respiratory Medicine, Shinko Hospital, Hyogo, Japan.
Naoto TakaseDepartment of Respiratory Medicine, Takarazuka City Hospital, Hyogo, Japan.
Yusuke MurakamiDepartment of Respiratory Medicine, National Hospital Organization Wakayama Hospital, Wakayama, Japan.
Kazuhiko MatsunoDepartment of Respiratory Medicine, Naha City Hospital, Okinawa, Japan.
Sumito InoueDepartment of Cardiology, Pulmonology, and Nephrology, Yamagata University Faculty of Medicine, Yamagata, Japan.
Akira KisoharaDepartment of Respiratory Medicine, Kasukabe Medical Center, Saitama, Japan.
Sojiro KusumotoDivision of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Hiroe AoshimaDepartment of Thoracic Surgery, Tokyo Women's Medical University, Tokyo, Japan.
Yumiko KakizakiLung Cancer and Respiratory Disease Center, Yamanashi Prefectural Central Hospital, Yamanashi, Japan.
Akihito KuboDepartment of Respiratory Medicine and Allergology, Aichi Medical University, Aichi, Japan.
Akito HataDivision of Thoracic Oncology, Kobe Minimally Invasive Cancer Center, Hyogo, Japan.
Nobuhisa IshikawaDepartment of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Kosuke HamaiDepartment of Respiratory Medicine, JA Onomichi General Hospital, Hiroshima, Japan.
Nobuhiro KanajiDepartment of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Toshihiro MisumiDepartment of Data Science, National Cancer Center Hospital East, Chiba, Japan.
Noriyuki MatsutaniDepartment of Thoracic Surgery, Shin-Yurigaoka General Hospital, Kanagawa, Japan.
Nobuhiko SekiDivision of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Objectives: To evaluate the therapeutic efficacy and safety of RAM + ERL as a first-line treatment for advanced or recurrent NSCLC harboring the L858R mutation in Japanese patients. Design: A multicenter, noninterventional, retrospective cohort study. Methods and analysis: This study will involve patients with advanced or recurrent NSCLC (ECOG PS score 0-2) with L858R mutation who received RAM + ERL between November 1, 2020 and August 31, 2023, with the planned sample size of 200 patients. The primary endpoint is time to treatment failure, and the secondary endpoints are overall survival, PFS, PFS2, time to discontinuation of any EGFR-TKI, time to failure of strategy, objective response rate, disease control rate, and safety. Exploratory endpoints are effects of ERL and RAM on PD-L1 expression and neutrophil-to-lymphocyte ratio. Discussion: To the best of our knowledge, this is the first retrospective study focusing on L858R mutations associated with the RELAY regimen, providing the corresponding real-world data. Trial registration: UMIN Clinical Trials Registry identifier: UMIN000052047.

Indexed as

erlotinibL858Rnon-small cell lung cancerramucirumab

Identifiers

PMID40535732
PMCPMC12174667

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.